What is Byrn, Inc.'s current financial performance?

Byrn, Inc. is currently not generating any revenue and continues to incur operating losses. For the three months ended June 30, 2026, the company reported a net loss of $178,646, a significant increase from the prior year period, mainly due to higher administrative expenses. Total liabilities have grown to $206,170 while assets remain minimal at $1,909.

What is the company's outlook regarding its ability to continue operating?

The company has stated that there is substantial doubt about its ability to continue as a going concern. It relies heavily on external financing to fund its operations and plans to raise additional capital. The company is actively exploring various sources of financing.

What is the new business direction for Byrn, Inc.?

Following the acquisition by MEDO Healthcare LLC, the company plans to rebrand as MEDO Technologies, Inc. The new business strategy involves acquiring pharmaceutical distributors nationwide and optimizing their operations using proprietary AI-based technology. This represents a significant shift from its previous focus.

What are the key risks associated with investing in Byrn, Inc. at this time?

Key risks include the company's lack of revenue and ongoing losses, its uncertain going concern status, the significant capital requirements for its new business plan, the potential for substantial dilution to existing shareholders from future financing, and material weaknesses in its internal controls. The success of the new business strategy is also a major unknown.

BRRN 10-Q Quarterly Report Q2 FY2026 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed August 14, 2026. Cited figures are marked; the original filing is the authoritative source.

Byrn, Inc. (BRRN) reported its financial results for the quarter ended June 30, 2026.

The company continues to operate without generating any revenue, reporting a net loss of $178,646^a for the three-month period, an increase from the $8,472 loss in the prior year's comparable quarter. This widening loss is primarily driven by significantly increased administrative expenses. Despite the ongoing losses, the company's financial position shows a growing liabilities balance, now standing at $206,170, while its total assets remain minimal at $1,909.

The company explicitly states substantial doubt regarding its ability to continue as a going concern, highlighting a need to raise additional funds and exploring various financing sources. The company is undergoing a significant strategic shift, with new management (MEDO Healthcare LLC) planning to rename the company to MEDO Technologies, Inc. The new business plan involves acquiring pharmaceutical distributors and optimizing them with AI-based technology.

This transition period is characterized by substantial operational and financial uncertainties, including the need for significant capital to fund acquisitions and potential dilution to existing shareholders from future financing. Investors should closely monitor the company's ability to execute its new business plan and secure necessary funding.

02—Key points

Key Highlights

No revenue generated for the quarter ended June 30, 2026, with continued operating losses.
Net loss for the three months ended June 30, 2026, increased to $178,646, up from $8,472 in the same period last year, driven by higher administrative expenses.
Total liabilities have increased to $206,170, while total assets remain minimal at $1,909 as of June 30, 2026.
The company expresses substantial doubt about its ability to continue as a going concern, necessitating the exploration of additional financing options.
New ownership (MEDO Healthcare LLC) plans to pivot the company's strategy towards acquiring pharmaceutical distributors and implementing AI technology, rebranding to MEDO Technologies, Inc.
Significant capital is required for planned acquisitions, with potential for substantial dilution to existing shareholders.
The company acknowledges material weaknesses in internal controls, including lack of segregation of duties and absence of an independent board/audit committee, with plans to address these post-acquisition.

03—Questions

Frequently Asked Questions

What is Byrn, Inc.'s current financial performance?
Byrn, Inc. is currently not generating any revenue and continues to incur operating losses. For the three months ended June 30, 2026, the company reported a net loss of $178,646, a significant increase from the prior year period, mainly due to higher administrative expenses. Total liabilities have grown to $206,170 while assets remain minimal at $1,909.
What is the company's outlook regarding its ability to continue operating?
The company has stated that there is substantial doubt about its ability to continue as a going concern. It relies heavily on external financing to fund its operations and plans to raise additional capital. The company is actively exploring various sources of financing.
What is the new business direction for Byrn, Inc.?
Following the acquisition by MEDO Healthcare LLC, the company plans to rebrand as MEDO Technologies, Inc. The new business strategy involves acquiring pharmaceutical distributors nationwide and optimizing their operations using proprietary AI-based technology. This represents a significant shift from its previous focus.
What are the key risks associated with investing in Byrn, Inc. at this time?
Key risks include the company's lack of revenue and ongoing losses, its uncertain going concern status, the significant capital requirements for its new business plan, the potential for substantial dilution to existing shareholders from future financing, and material weaknesses in its internal controls. The success of the new business strategy is also a major unknown.

04—Continue

← View all 10-Q filings